Vanta Bioscience

Vanta Bioscience FCF Margin

The Free Cash Flow Margin of Vanta Bioscience (540729.BO) as of Oct 18, 2026 is -463.56 %. In the previous year, Free Cash Flow Margin was -7.41 % — a change of 6,153.66% (lower).

FCF Margin

-463.56 %

YoY

6,153.66%

Last updated:

Free Cash Flow Margin of Vanta Bioscience is 2025 -463.56 % . Free Cash Flow Margin of Vanta Bioscience was 2024 -7.41 % . It decreases by 6,153.66% lower compared to the previous year.

The Vanta Bioscience FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2019
-30.14 INR
Jan 1, 2020
-37.09 INR
Jan 1, 2021
-152.67 INR
Jan 1, 2022
-123.44 INR
Jan 1, 2023
-467.13 INR
Jan 1, 2024
-7.41 INR
Jan 1, 2025
-463.56 INR
The Vanta Bioscience FCF Margin history
YEARFCF MarginYoY
-463.56 %+6,153.66%
-7.41 %-98.41%
-467.13 %+278.42%
-123.44 %-19.15%
-152.67 %+311.59%
-37.09 %+23.09%
-30.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vanta Bioscience Stock analysis

What does Vanta Bioscience do? Vanta Bioscience Ltd is a company operating in the Health Care sector, specifically within the Life Sciences Tools & Services industry. Headquartered in Secunderabad, India, the company provides preclinical contract research services. It went public through an IPO on October 6, 2017. Vanta Bioscience offers a range of services including testing and contract research in clinical research, pre-clinical research, biopharma services, analytical testing, and environmental studies. The company serves clients from various industries such as pharmaceuticals, medical devices, nutraceuticals, feed additives, biotechnology, agrochemicals, cosmetics, and chemicals. Their services include preclinical safety assessment, risk assessment for active pharmaceutical ingredients (APIs), excipients, extractables and leachables, and pharmaceutical impurities. Additionally, Vanta Bioscience provides services for determining health-based exposure limits, such as permitted daily exposure (PDE) or allowable daily exposure (ADE), as well as occupational exposure limits (OEL) for pharmaceutical manufacturers. The company's website is www.vantabio.com. Vanta Bioscience Ltd is listed on the Bombay Stock Exchange under the ticker 540729.BO and has the ISIN INE695X01011. The company focuses on delivering comprehensive preclinical research solutions to support the development and safety evaluation of products across multiple sectors. Vanta Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vanta Bioscience stock

Free Cash Flow Margin of Vanta Bioscience is -463.56 % in 2025.

Free Cash Flow Margin of Vanta Bioscience changed from -7.41 % to -463.56 %, representing a 6,153.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Vanta Bioscience since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Vanta Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Vanta Bioscience

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Vanta Bioscience